Lizhi Zhang1, Peicheng Li1, Zhaosheng Tang1, Qin Dou2, Bo Feng1. 1. Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China. 2. Department of Clinical Laboratory, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Abstract
BACKGROUND: It has been reported that glucagon-like peptide-1 (GLP-1) can alleviate diabetic osteoporosis (DOP). This study was to investigate the effects of GLP-1RA liraglutide and dipeptidyl peptdase-4 (DPP-4) inhibitor vildagliptin on the advanced glycation end products (AGEs)-induced bone injury in ApoE-/- mice with euglycemia. METHODS: The bone markers OC, PINP, PTH, TRACP and CTX, the mRNA and protein expressions of RAGE in the femur, and the femoral morphology index were determined to evaluate whether the osteoporosis was improved by liraglutide or vildagliptin. RESULTS: AGEs adversely affected the bone metabolism, characterized by reduced OC and increased CTX. However, vildagliptin reduced AGEs and increased OC, and liraglutide significantly decreased AGEs and PTH. Both vildagliptin and liraglutide had no effects on the bone metrology and RAGE expression in the femurs of ApoE-/- mice. CONCLUSIONS: The elevated AGEs may exacerbate osteogenesis and increase bone resorption, and vildagliptin/liraglutide may improve bone metabolism.
BACKGROUND: It has been reported that glucagon-like peptide-1 (GLP-1) can alleviate diabetic osteoporosis (DOP). This study was to investigate the effects of GLP-1RA liraglutide and dipeptidyl peptdase-4 (DPP-4) inhibitor vildagliptin on the advanced glycation end products (AGEs)-induced bone injury in ApoE-/- mice with euglycemia. METHODS: The bone markers OC, PINP, PTH, TRACP and CTX, the mRNA and protein expressions of RAGE in the femur, and the femoral morphology index were determined to evaluate whether the osteoporosis was improved by liraglutide or vildagliptin. RESULTS: AGEs adversely affected the bone metabolism, characterized by reduced OC and increased CTX. However, vildagliptin reduced AGEs and increased OC, and liraglutide significantly decreased AGEs and PTH. Both vildagliptin and liraglutide had no effects on the bone metrology and RAGE expression in the femurs of ApoE-/- mice. CONCLUSIONS: The elevated AGEs may exacerbate osteogenesis and increase bone resorption, and vildagliptin/liraglutide may improve bone metabolism.
Entities:
Keywords:
ApoE−/− mice; advanced glycation end product (AGE); bone metabolism; diabetic osteoporosis (DOP); dipeptidyl peptdase-4 inhibitor; glucagon-like peptide-1 (GLP-1)
Authors: Ke-Hong Ding; Zai-Zhao Wang; Mark W Hamrick; Zhong-Bin Deng; Li Zhou; Baolin Kang; Sheng-Li Yan; Jin-Xiong She; David M Stern; Carlos M Isales; Qing-Sheng Mi Journal: Biochem Biophys Res Commun Date: 2005-12-27 Impact factor: 3.575
Authors: A S Plump; J D Smith; T Hayek; K Aalto-Setälä; A Walsh; J G Verstuyft; E M Rubin; J L Breslow Journal: Cell Date: 1992-10-16 Impact factor: 41.582